CRVS - Corvus: Surging On AstraZeneca CD73 Success With Key Data Readout Looming

• Corvus stock has made spectacular gains across the past week, rising from a price of $2.3 to $8.5 - a 270% gain.
• Last week, AstraZeneca's Oleclumab - an anti-CD73 therapy - substantially improved the risk of death in combo with IMFINZI in NSCLC.
• Corvus' Mupadolimab is an anti-CD73 monoclonal antibody and hopes are high that it can show similar efficacy to Oleclumab.
• Corvus recently discontinued the development of Mupadolimab as a COVID therapy and resumed trials of the drug in head and neck cancer.
• Data from that trial, and an expansion cohort in combo with Merck's Keytruda, ought to read out this year - a potentially exciting catalyst. Corvus deserves its recent uplift, in my view, but still has much to prove.

For further details see: